Press Releases 2018-11-01T18:25:47+00:00

Press Releases


NOVEMBER 1, 2018

OsteoRemedies® Announces the First FDA Cleared Dual-Antibiotic Spacer and Bone Cement with Gentamicin and Vancomycin

Memphis, TN, (DATE) — OsteoRemedies®, LLC, a company focused on providing simple solutions to complex disorders, is pleased to announce the launch of the REMEDY SPECTRUM™️ GV Hip Spacer System and SPECTRUM™️ GV Bone Cement. Building on its portfolio consisting of the only pre-made modular spacer system with Gentamicin for Hip, Knee and Shoulders, the REMEDY SPECTRUM™️ GV Hip System will provide surgeons with the first ever broad-spectrum treatment option with both Gentamicin and Vancomycin.

“We are very proud to have the first FDA cleared dual-antibiotic spacer system and bone cement offering”, stated Chris Hughes, President and Chief Executive Officer of OsteoRemedies®. “Since we started the company in 2013, our commitment to the growing problem of treating joint infections has been our mission. The amount of science, testing and clinical data supporting this launch is unparalleled in our space. The addition of the SPECTRUM™️ GV portfolio, further enhances our vision for providing simple solutions for complex disorders for revision infection remedies and achieving a market leadership position in our niche”.

The launch of the SPECTRUM™️ GV system will begin November 1-4 at the American Academy of Hip and Knee Surgeons (AAHKS) in Dallas, Texas where OsteoRemedies® will be exhibiting at Booth # 308. In addition to the introduction of SPECTRUM™, OsteoRemedies® will also be showcasing the newly launched REMEDY® Acetabular Cup Spacer, which in conjunction with the REMEDY® Hip System, provides the only Pre-formed all PMMA hip spacer option on the market. The existing portfolio will also be displayed, including the REMEDY® Modular Hip, Knee and Shoulder Spacer, OSTEOBOOST®️ RBK and FLORASEAL®️ Microbial Sealant along with UNITE® Antibiotic Bone Cement.

About OsteoRemedies®, LLC

OsteoRemedies provides simple solutions to complex musculoskeletal disorders. Their first introduction was the REMEDY® Spacer System. This was the first available modular system for hip, knee and shoulder two-stage infection revision arthroplasty. The REMEDY® Spacer System and REMEDY SPECTRUM™️ GV Hip Spacers are indicated for temporary use (maximum 180 days) as an adjunct to total joint replacement in skeletally mature patients undergoing a two-stage procedure due to a septic process and where gentamicin or gentamicin and vancomycin are the most appropriate antibiotics based on the susceptibility pattern of the infecting micro-organisms. SPECTRUM™ GV Bone Cement is indicated for use with the REMEDY SPECTRUM™ GV Hip Spacer System. Other product offerings include OSTEOBOOST®️ RBK and FLORASEAL®️ Microbial Sealant and UNITE®️ AB Bone Cement.

The Company’s web site for news releases and other information is

Eric Stookey
[email protected]

JULY 26, 2017

OsteoRemedies® introduces FLORASEAL® in exclusive private label distribution agreement with Adhezion Biomedical LLC

OsteoRemedies LLC introduces its latest product FLORASEAL Microbial Sealant through an exclusive US distribution agreement with Adhezion Biomedical LLC. FLORASEAL is a patented film-forming, cyanoacrylate-based microbial sealant intended to reduce the risk of skin flora contamination throughout the surgical procedure. FLORASEAL acts as a physical barrier to microbial penetration as long as the sealant film remains intact. Studies have shown that FloraSeal typically stays on the skin for 5-7 days. The use of an incise drape with FLORASEAL sealant is not necessary. “FLORASEAL is a perfect fit to our portfolio of infection related products and coincides with our vision to be the premier choice for surgeons by providing simple solutions to complex disorders focused on revision and infection remedies,” said Chris Hughes, Founder and CEO of OsteoRemedies. “With Adhezion’s commitment and expertise to cyanoacrylate-based microbial sealant adhesive and infection prevention products, I believe this is the ideal partnership for OsteoRemedies,” added Hughes.

About OsteoRemedies LLC

OsteoRemedies is a Memphis, TN company focused on providing simple solutions to complex disorders for revision and infection remedies. OsteoRemedies currently provides REMEDY® Spacer System, the only pre-molded modular spacer system, and UNITE® Antibiotic Bone Cement for 2 stage revision of infected hip, knee and shoulder total joints. OsteoRemedies also provides OSTEOBOOST® Resorbable Bead Kit, the only tri-phasic bone void filler in bead kit formulation. To learn more about OsteoRemedies and its products, please visit

About Adhezion Biomedical LLC

Adhezion Biomedical is a privately held medical device company based in Wyomissing, PA. Adhezion is committed to developing and manufacturing medical cyanoacrylate products used in the treatment of wound closure, wound management, intravenous device securement and infection prevention. To learn more about Adhezion and its products, please visit


Eric Stookey
Chief Operating Officer
[email protected]

Direct link:

MARCH 17, 2015

OsteoRemedies® appoints Eric A. Stookey as Chief Operating Officer

OsteoRemedies, LLC, a company focused on providing simple solutions to complex disorders currently not addressed in the musculoskeletal market, is pleased to announce Eric A. Stookey has been appointed Chief Operating Officer, effective March 1, 2015.

“In 2015, we plan to introduce new products, enter new markets, and expand our hip and knee surgeon network,” stated Chris Hughes, President and Chief Executive Officer of OsteoRemedies. “Eric’s tremendous experience and pattern of success in orthopedics is exactly what we need to successfully execute our strategic plan and allow OsteoRemedies to uniquely serve our surgeon customers’ clinical needs.”

Prior to joining OsteoRemedies, Mr. Stookey most recently served as the President of the Extremities-Biologics division at Wright Medical Group, Inc. (Nasdaq:WMGI) until August 2014. Mr. Stookey served in various other marketing and sales positions at Wright Medical Group, Inc. since 1995, including the Senior Vice President and Chief Commercial Officer, Vice President North American Sales, Senior Director of Sales – Central Region, and Director of Marketing for Large Joint Reconstruction Products. He also worked for DePuy Orthopedics, Inc. from 1993 to 1995.

Mr. Stookey earned his Masters of Business Administration degree from Christian Brothers University and his Bachelor of Science degree in Business from the Indiana University School of Business. In addition to his new role as Chief Operating Officer, Mr. Stookey will continue to serve as an independent member of the Board of Directors for both Amedica Corporation, Salt Lake City, UT (Nasdaq: AMDI) and Cartiva, Inc., Alpharetta, GA.

“I am delighted to be joining the OsteoRemedies team to help build upon the excellent foundation and momentum Chris has established over the past 12 months,” stated Mr. Stookey. “We absolutely share a vision for addressing unmet needs that allow clinicians to better treat their patients, and I’m excited to work with the world-class distributors to further expand this organization.”

OsteoRemedies will be exhibiting at the upcoming American Academy of Orthopedic Surgeons (AAOS), in Las Vegas, NV, on March 25-27 (Booth #4665). As part of this event, they will be displaying current differentiated products like the REMEDY® Spacer, UNITE® Antibiotic Bone Cement and unveiling new revision offerings that will further address unmet needs in the US orthopedic market.

About OsteoRemedies, LLC

OsteoRemedies provides simple procedural solutions to complex musculoskeletal disorders. Their first introduction in the orthopaedic market was the REMEDY Spacer System. This is the first FDA-approved modular system available for both hip and knee two-stage infection revision arthroplasty. The REMEDY Spacer is indicated for temporary use (maximum 180 days) as an adjunct to total hip or knee replacement in skeletally mature patients undergoing a two-stage procedure due to a septic process and where gentamicin is the most appropriate antibiotic based on the susceptibility pattern of the infecting micro-organisms. Their second product was the UNITE AB Bone Cement product line. UNITE is available in a 40 gram batch loaded with gentamicin.

Chris Hughes
President and CEO
901- 849-5656

Direct link:

MARCH 3, 2015

6 Questions with Chris Hughes, an entrepreneur who is challenging conventional thinking in Orthopedics

This is the first in a series of 6-Question interviews with the leaders who are challenging conventional thinking in Orthopedics.

I have known Chris Hughes for over a decade. After serving in the Army, he rose through the ranks of Sales and Marketing in Orthopedics and Spine, the latter with Medtronic Spine & Biologics and two start-up ventures. In 2008, he threw himself into his first startup as President of Paradigm Spine, a Viscogliosi portfolio company. He now heads up an innovative startup called OsteoRemedies® that is thinking differently. Chris is the President and CEO. I sat down with Chris and asked him a few questions.

1. What were the origins of OsteoRemedies? Tell us how it all started.

Chris Hughes: I founded OsteoRemedies in September of 2013. A few months prior to this, a group with the IP approached me wanting to introduce their ideas to the US market. I was immediately impressed with the progress they had made with design, regulatory approvals, as well as pre-clinical and biomechanical data. As I researched the market potential, I realized quickly that this was a great alternative in a very differentiated space. I recall discussing with my family, a few mentors, friends and potential business partners that I would need help from them to get things started. The support was overwhelming. So I searched a few potential company names, hired The Robinette Group to help develop our brand, logo, and image and we were off! It was exciting to literally “start-up” from the napkin. Our first introduction was at the CCJR meeting in December of 2013, where my primary goal was to find several high quality distributors. At the time, I had product being manufactured and was focused on developing a brand, vision, goals and refining our strategic plan. I was overwhelmed with the reception from some of the largest, best independent agents in the country.  I look back and it was lonely on that island booth with no products to sell and no sales force, but I knew we had a great story and a compelling opportunity.

My vision then, when starting OsteoRemedies, and still today is to provide simple procedural solutions to complex musculoskeletal disorders not addressed in the market today. Our REMEDY® Antibiotic Spacers and UNITE® Antibiotic Bone Cement address the first of several markets we have targeted. In the near-term, we will enter new markets while ensuring we stay true to providing simple, differentiated solutions to complex problems.

2. How is OsteoRemedies funded and why have you chosen Memphis as a base?

Chris Hughes: We are fully funded by the group that approached me in 2013. OsteoRemedies is not your typical start-up; we are not funded by a VC firm or traditional “exit focused” investors. I believe this allows for a more pure management driven strategic plan that is focused on customers, sales, operations, cash flow and growth. In the past, I have been fortunate to work with small, medium and large organizations, ranging from cash rich market leaders to boot strapped start-ups. The greatest lesson I have learned is that cash is king. That is top of mind in all decisions we make; as long as it allows us to ensure our mantra of ALWAYS meeting our customer needs.

As for location, Memphis was a no brainer. I have lived here now for 18 years and have come to appreciate its numerous business advantages.  As we grow, there are 4000 plus medical device employees to attract and recruit. We have first-class, multi-disciplinary physician practices in town, world-renowned hospitals, FedEx, Millstone Medical Outsourcing and several bioscience companies, all centrally located in the U.S., with an excellent cost of living. You add it all up and Memphis is a great choice for any medical device start-up.

3.  Who are OsteoRemedies’ targeted customers?

Chris Hughes: Currently we focus on providing simple procedural solutions to surgeons who perform Hip and Knee Revision Arthroplasties. As we develop and launch new products, we will continue to target segments of the market where we can address unmet needs for the clinicians we serve. Our goal is to be the “Premier Choice” in these markets and not compete in the commodity musculoskeletal spaces. In other words, we are not focused on pedicle screws, cages, primary hips and knees or plates and screws. We are very interested in serving the clinicians that use these products, but only where we can help the medical industry solve meaningful clinical issues, provide economic value, while creating barriers to entry that protect the sustainability of our business and the interests of the world-class distributors that carry our products.

4. What makes the REMEDY Knee and Hip spacer different from other antibiotic spacers on the market such as Biomet’s StageOne mold?

Chris Hughes: From both our view, and the feedback from our customers, we see many advantages including simplicity, modularity, interchangeability, strength, elution profile of the antibiotics over time, proper sizing and cost effectiveness. Unlike some competitive options, our spacers are pre-made, saving the surgeon time in the OR which saves the facility money.

Our hip system is modular with 6 stems and 3 interchangeable heads, allowing for proper fit, both in component size and through tensioning with    our unique variable offset design. Our knee-size combinations are totally interchangeable, allowing surgeons to address situations where they want or need to mis-match constructs. We have the only system that offers wedge augments (10 mm height) that allow the surgeon to replicate the joint space defects. Because REMEDY Spacers are pre-made; they are manufactured in a controlled environment. This provides a consistent blend of our PMMA and Antibiotics that cannot be replicated with hand-made molds. This proper mixture also yields superior mechanical strength, which is critical for a weight-bearing spacer. Off-the-shelf cements mixed in molds are designed for fixating devices and filing gaps but were not intended to be articulating joint replacements. Our formulation and geometry also allows for elution of the antibiotics over time where mold designs have shown in the literature to “trap the excess or wasted antibiotics” in the mold after 24 hours. Simply put, the REMEDY Spacer System is simple, strong and both clinically and cost effective.

5. What are the challenges of breaking into this market?

Chris Hughes: Distribution is one of the critical requirements for success in medical device markets. The challenge we face as a small start up is reaching our surgeon customers. We are fortunate to have attracted some of the best distributors nationwide this past year. I was so busy after the CCJR making product, developing marketing materials and signing-up distributors. Time was literally flying by. A few months later we launched at AAOS. I remember driving down to New Orleans with a new company, new brand, new booth and a few distributors ready to sell. I left AAOS with 26 distributors carrying our spacers and cement and we just ramped. It was fun, and I am still energized by the excitement of the distributors and customers about our products. Today, we now have over 40 distributors carrying our products and we are excited for our second AAOS in Las Vegas.

6.  What are OsteoRemedies goals for the next few months and years?

Chris Hughes: Our goal for the next few months is growth. We had a great first year but I always say, never fast enough and never enough. This year we plan to grow sales, personnel and enter new differentiated markets where we can offer surgeons solutions to complex problems. We also plan to help our distributor partners grow their business. I believe our products can continue to help them increase revenues with OsteoRemedies, but just as strategically important, can help them grow their respective main lines too. The REMEDY Spacer, UNITE Antibiotic Cement and our new revision offerings (to be unveiled at AAOS) can open doors for our sales force.

I am also proud to announce, that effective March 1st, Eric Stookey joined OsteoRemedies as Chief Operating Officer. Eric has 20 years experience in orthopedics most recently as President, Wright Medical, Extremities and Biologics. Eric and I started in marketing together 18 years ago.  After two years we went different paths in Orthopedics and Spine but maintained our professional and personal relationship. For OsteoRemedies, it is an ideal time for business expansion and a pleasure having Eric on board to collaborate with, further develop and grow OsteoRemedies. Our goal over the next few years is to continue providing simple solutions to complex disorders currently not addressed in the musculoskeletal market, thus allowing the valued customers we serve to restore their patients’ lives!